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Summary
Background Pneumococcal conjugate vaccines (PCVs) are used in many low-income countries but their impact on the 
incidence of pneumonia is unclear. The Gambia introduced PCV7 in August, 2009, and PCV13 in May, 2011. We 
aimed to measure the impact of the introduction of these vaccines on pneumonia incidence.
Methods We did population-based surveillance and case-control studies. The primary endpoint was WHO-defined 
radiological pneumonia with pulmonary consolidation. Population-based surveillance was for suspected pneumonia 
in children aged 2–59 months (minimum age 3 months in the case-control study) between May 12, 2008, and 
Dec 31, 2015. Surveillance for the impact study was limited to the Basse Health and Demographic Surveillance System 
(BHDSS), whereas surveillance for the case-control study included both the BHDSS and Fuladu West Health and 
Demographic Surveillance System. Nurses screened all outpatients and inpatients at all health facilities in the 
surveillance area using standardised criteria for referral to clinicians in Basse and Bansang. These clinicians recorded 
clinical findings and applied standardised criteria to identify patients with suspected pneumonia. We compared the 
incidence of pneumonia during the baseline period (May 12, 2008, to May 11, 2010) and the PCV13 period (Jan 1, 
2014, to Dec 31, 2015). We also investigated the effectiveness of PCV13 using case-control methods between 
Sept 12, 2011, and Sept 31, 2014. Controls were aged 90 days or older, and were eligible to have received at least one 
dose of PCV13; cases had the same eligibility criteria with the addition of having WHO-defined radiological 
pneumonia.
Findings We investigated 18 833 children with clinical pneumonia and identified 2156 cases of radiological pneumonia. 
Among children aged 2–11 months, the incidence of radiological pneumonia fell from 21·0 cases per 1000 person-
years in the baseline period to 16·2 cases per 1000 person-years (23% decline, 95% CI 7–36) in 2014–15. In the 
12–23 month age group, radiological pneumonia decreased from 15·3 to 10·9 cases per 1000 person-years 
(29% decline, 12–42). In children aged 2–4 years, incidence fell from 5·2 to 4·1 cases per 1000 person-years (22% 
decline, 1–39). Incidence of all clinical pneumonia increased by 4% (–1 to 8), but hospitalised cases declined by 8% 
(3–13). Pneumococcal pneumonia declined from 2·9 to 1·2 cases per 1000 person-years (58% decline, 22–77) in 
children aged 2–11 months and from 2·6 to 0·7 cases per 1000 person-years (75% decline, 47–88) in children aged 
12–23 months. Hypoxic pneumonia fell from 13·1 to 5·7 cases per 1000 person-years (57% decline, 42–67) in children 
aged 2–11 months and from 6·8 to 1·9 cases per 1000 person-years (72% decline, 58–82) in children aged 12–23 months. 
In the case-control study, the best estimate of the effectiveness of three doses of PCV13 against radiological pneumonia 
was an adjusted odds ratio of 0·57 (0·30–1·08) in children aged 3–11 months and vaccine effectiveness increased with 
greater numbers of doses (p=0·026). The analysis in children aged 12 months and older was underpowered because 
there were few unvaccinated cases and controls.
Interpretation The introduction of PCV in The Gambia was associated with a moderate impact on the incidence of 
radiological pneumonia, a small reduction in cases of hospitalised pneumonia, and substantial reductions of 
pneumococcal and hypoxic pneumonia in young children. Low-income countries that introduce PCV13 with 
reasonable coverage can expect modest reductions in hospitalised cases of pneumonia and a marked impact on the 
incidence of severe childhood pneumonia.
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Introduction
In 2013, pneumonia caused an estimated 935 000 childhood 
deaths worldwide.1 The most common cause of severe 
pneumonia is Streptococcus pneumoniae2−4 and pneumonia 
is estimated to cause 90% of pneumococcal deaths.5 In 
high-income countries, pneumococcal conjugate vaccines 
(PCVs) have reduced the incidence of childhood 
pneumonia.6−8 54 low-income countries have introduced 
PCV, yet data from these settings on the effect of the 
vaccine against pneumonia are scarce.
The Gambia has a high burden of pneumonia.9 Results 
from a trial of a nonavalent PCV (PCV9) in The Gambia 
from 2000 to 2004, showed an efficacy of 37% against 
WHO-defined radiological pneumonia and that 58% of 
radiological pneumonia was caused by the PCV9 
serotypes.9 The Government of The Gambia introduced 
PCV7 into the Expanded Programme on Immunisation 
(EPI) on Aug 19, 2009. The schedule consisted of three 
doses given at ages 2, 3, and 4 months. Children younger 
than 6 months were eligible to receive all three doses, 
whereas older children were eligible for one dose. There 
was no catch-up campaign. PCV13 was introduced at EPI 
clinics in the study area during May, 2011, using the same 
three-dose schedule. In this study, we aimed to measure 
the impact and effectiveness of routine infant vaccination 
with PCV on pneumonia in children in The Gambia.
Methods
Surveillance study
We did population-based surveillance for suspected 
pneumonia, septicaemia, and meningitis in the Basse 
Health and Demographic Surveillance System (BHDSS; 
appendix p 8; population of 171 269 in 2012) between 
May 12, 2008, and Dec 31, 2015. The surveillance 
population included all residents aged 2 months or older 
and was enumerated every 4 months. This surveillance 
analysis was restricted to children aged 2–59 months.
Case-control study
We did a case-control study to estimate the effectiveness of 
PCV13 against radiological pneumonia with con solidation 
between Sept 12, 2011, and Sept 31, 2014. During this 
period, surveillance was extended to all residents younger 
than 5 years in the Fuladu West Health and Demographic 
Surveillance System (FWHDSS; appendix p 8), as well as 
in the BHDSS. The FWHDSS population was enumerated 
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Research in context
Evidence before this study
We did a systematic literature search on PubMed, Embase, and 
Web of Science for observational studies of the impact of 
pneumococcal conjugate vaccine (PCV) published between Jan 
1, 2008, and Jan 15, 2017. We searched PubMed using the MeSH 
terms “pneumococcal vaccines”, “vaccines, conjugate”, 
“pneumonia”, and the (All Fields) terms “pneumococcal”, 
“conjugate vaccines”, “pneumonia”, “impact”, and 
“effectiveness”, restricting the search to childhood populations. 
For other data sources, we used the key search terms as above. 
We searched for prospective case-control and population-based 
longitudinal studies of childhood pneumonia that included at 
least 2 years of data following the introduction of PCV. After 
reviewing 225 articles, 27 met inclusion criteria; PCV7 impact 
was measured in eight, PCV10/13 impact in 19, and three were 
case-control studies. We found no eligible reports from low-
income countries. Reports varied in quality and most reported 
administrative data on hospital admissions without ensuring 
consistency of procedures for the investigation of patients. The 
reports showed consistent evidence of an overall reduction of 
variable magnitude in childhood hospital admissions coded as 
pneumonia after the introduction of PCV7 (13–43%) and 
PCV10/13 (13–72%). Studies of the impact of PCV10/13 showed 
consistent evidence of an overall reduction in hospital 
admissions with radiological pneumonia (16–72%) and WHO-
defined radiological pneumonia with consolidation (27–47%). 
Case-control studies reported 21–39% effectiveness against 
presumed bacterial pneumonia, 77% effectiveness 
against pneumococcal pneumonia, and 72% effectiveness 
against death from pneumonia.
Added value of this study
This study showed substantial relative and absolute reductions 
in severe pneumonia in young children 4 years after the 
introduction of PCV13. We report reductions in the standard 
endpoints of hospital admission for pneumonia and 
WHO-defined radiological pneumonia with consolidation, 
as well as large reductions in proven pneumococcal and hypoxic 
pneumonia. This study used standardised procedures for 
prospective case ascertainment over 8 years and thus provides 
new and robust evidence of the impact of PCV introduction on 
pneumonia in a low-income country. Our findings are relevant 
to many low-income countries because the study was based in 
a typical African population, where the PCV programme used a 
standard schedule without a catch-up campaign, as is the case 
in almost all low-income countries. These data will be valuable 
to countries that need data from a low-income country to 
support their policy and financing for pneumococcal 
vaccination.
Implications of all available evidence
The routine use of PCV13, with a standard schedule and 
reasonable coverage, will reduce the burden of hospital 
admissions for pneumonia and substantially reduce severe 
pneumonia in low-income and middle-income countries, 
where pneumococcal disease burden and deaths are greatest. 
The ongoing burden of pneumonia emphasises the importance 
of developing new vaccines and interventions. Robust data to 
assess the impact of PCV in Africa and Asia are scarce and 
ongoing high-quality impact studies provide crucial data to 
inform global decision making about vaccination with PCV.
See Online for appendix
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annually. Cases had WHO-defined radiological 
pneumonia and were aged 90 days or older (ie, aged ≥3 
months) and eligible to have received at least one dose of 
PCV13; matched community controls had to meet the 
same eligibility criteria, with the exception of the 
radiological pneumonia. All cases in both the surveillance 
and case-control studies were confirmed residents in the 
study area. Children who had received three doses of 
PCV7 were ineligible for the case-control study and those 
who had received one or more dose of PCV7 were excluded 
from the case-control analysis. Cases and controls were 
excluded if they had a major congenital abnormality or 
suspected or confirmed immune deficiency. Individuals 
were eligible to be selected as controls more than once but 
were ineligible if they had previously been enrolled as a 
case (appendix p 5). For each case, three community 
controls were randomly selected from the population 
register matched on the date of birth plus or minus 
15 days. Controls were enrolled at home visits within 
3 months of case enrolment.
Procedures
The surveillance methods have been described 
previously.11,12 In brief, nurses screened all outpatients 
and inpatients at all health facilities in the BHDSS and 
FWHDSS using standardised criteria for referral to 
clinicians in Basse and Bansang (appendix p 18). 
Screening included measurement of O2 saturation with a 
pulse oximeter (Nellcor N-65, Covidien, Boulder, CO, 
USA). Clinicians recorded clinical findings and applied 
standardised criteria to identify patients with suspected 
pneumonia, septicaemia, or meningitis, and requested 
blood culture, lumbar puncture, or chest radiography in 
accordance with a standardised protocol (appendix, 
pp 19, 20). Aspiration of pleural fluid or lung aspiration 
was done for selected patients with pleural effusions or 
large, dense, peripheral consolidation. All enrolled 
patients underwent rapid malaria tests (ICT Diagnostics, 
Cape Town, South Africa) from August to December (the 
malaria transmission season) every year. Surveillance 
was interrupted between Oct 5 and Nov 3, 2010, when the 
field station flooded.
Radiographs were obtained with consistent methods to 
produce digital images in accordance with WHO 
recommendations.10 Radiographs were read by two 
independent readers and readings discordant for end-
point con solidation were resolved by a paediatric 
radiologist. All readers were calibrated to the WHO 
standard, achieving κ scores of 0·8 or higher before 
reading radiographs.
For the case-control study, radiographs were read in real 
time by two independent readers with discordant readings 
resolved by a third reader. All readers were recalibrated to 
the WHO standard every 6 months achieving κ scores of 
0·7 or higher before continuing to read radiographs. 
Vaccination dates were recorded from hand-held cards and 
in real time at maternal-child-health clinics in the BHDSS. 
Standardised questionnaires were used to collect data on 
risk factors and potential confounders (appendix p 24).
Laboratory samples for the surveillance study were 
processed in Basse with consistent standardised 
methods.13 S pneumoniae was identified by morphology 
and optochin sensitivity. Pneumococcal isolates were 
serotyped at the Medical Research Council (MRC) Fajara 
laboratory, by use of latex agglutination.12
The Gambia Government/MRC Joint Institutional 
Ethics Committee (number 1087) and the London School 
Figure 1: Study profile
The profile covers the longitudinal observation period in the BHDSS from 
May 12, 2008, to Dec 31, 2015. 1920 cases had radiological pneumonia with 
consolidation, 17 136 had clinical pneumonia, 265 had pneumococcal 
pneumonia, and 672 had hypoxic pneumonia. All values are crude. The 
adjustment corrects for trends in the rate of patients presenting who met 
referral criteria. BHDSS=Basse Health and Demographic Surveillance System.
BHDSS residents 
146 876 in 2008
179 400 in 2015
Non-BHDSS residents 
using BHDSS 
health facilities
 175 declined referral
 72 failed referral
 13 553 no endpoint consolidation
 9 undetermined
 1654 no chest radiograph
 789 resident outside BHDSS
 520 aged 0–60 days
 1917 aged ≥5 years
 516 not clinical pneumonia,
  septicaemia, or meningitis
 727 clinical septicaemia or
  meningitis only
21 852 patients presented to BHDSS 
 health facilities and met criteria 
 for referral to clinician
17 136 met criteria for clinical pneumonia
 7606 aged 2–11 months
 5223 age 12–23 months
 4307 aged 2–4 years
15 482 chest radiographs 
 7049 aged 2–11 months
 4783 aged 12–23 months
 3650 aged 2–4 years
1920 cases of endpoint consolidation
 774 aged 2–11 months
 588 aged 12–23 months
 558 aged 2–4 years
21 605 assessed by clinician
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of Hygiene & Tropical Medicine ethics committee 
approved the study. Parents or guardians of study 
participants gave written informed consent.
Outcomes
The primary endpoint was radiological pneumonia with 
consolidation, as defined by WHO.10 Secondary endpoints 
were radiological pneumonia with consolidation plus 
isolation of S pneumoniae from a sterile site (blood, 
cerebrospinal fluid, lung aspirate, or pleural fluid); clinical 
pneumonia, defined as cough or difficulty breathing for 
less than 14 days accompanied by one or more of raised 
respiratory rate for age, lower chest wall indrawing, nasal 
flaring, grunting, O2 saturation less than 92%, altered 
consciousness, inability to sit or feed, convulsions, dull 
chest percussion note, coarse crackles, or bronchial 
breathing; clinical pneumococcal pneumonia (defined as 
for clinical pneumonia with the addition of isolation of 
S pneumoniae from a sterile site; and hypoxic pneumonia, 
defined as clinical pneumonia with peripheral 
O2 saturation less than 90%.
We further categorised pneumococcal pneumonia 
outcomes according to PCV13 serotype (1, 3, 4, 5, 6A, 6B, 
7F, 9V, 14, 18C, 19A, 19F, and 23F) or non-PCV13 serotype 
groups. We defined the exploratory endpoint of 
bronchiolitis as clinical pneumonia with wheeze 
detectable on auscultation without dullness to percussion, 
bronchial breathing, or radiological pneumonia.
Statistical analysis
We calculated annual incidence of each type of pneumonia 
by dividing number of cases by the mid-year population 
estimates from the BHDSS. To calculate annual incidence 
in 2008 and 2010, we used the number of observed cases to 
extrapolate the unobserved cases from Jan 1 to May 11, 2008, 
and during the flood in 2010 (appendix p 3). Repeated 
episodes in an individual were included if they were 
separated by more than 30 days. We adjusted for observed 
increases in the number of children referred to clinicians 
per unit population over time by multiplying annual event 
counts by a correction factor that assumed the rate of 
referral in the absence of bias was constant (appendix p 4).12
We calculated the ratio of the incidence in the last 2 years 
of surveillance (2014–15) to the incidence in the baseline 
first 2 years (May 12, 2008, to May 11, 2010; ie, extrapolated 
cases were not included). We assumed a Poisson 
distribution to calculate incidence rate ratios (IRRs) and 
95% CIs. CIs for the 2–4 year age group were inflated to 
allow for over dispersion, which was estimated from a 
subject-level Poisson regression analysis of radiological 
pneumonia data from 2008 to 2009. Categorical analyses 
used Fisher’s exact test. Statistical significance was set at a 
p value of less than 0·05. We used STATA version 12.1 and 
MATLAB version R2015a for the analyses.
To investigate potential bias due to temporal changes 
in health-care seeking, patient investigation, or con-
founding by secular trends in epidemic serotypes, we did 
three a-priori stratified analyses, which excluded out-
patients, cases identified by lung aspiration alone, and 
cases caused by serotype 1 or 5. To assess the effect of 
temporal trends related to bacterial pneumonia, we 
evaluated the incidence of clinical pneumonia due to 
bacteria other than pneumococcus as a control condition. 
We also evaluated the prevalence of malnutrition and 
malaria over time in patients with suspected pneumonia.12
The sample size for the case-control study assumed 
three-dose coverage of 90% in controls. Enrolment of 
881 cases with three controls each would have 80% power 
to detect vaccine effectiveness of 35% at a significance 
level of 5%. We used conditional logistic regression to 
estimate odds ratios of radiological pneumonia for three 
compared with zero doses of PCV13 and to test for trend 
by number of doses. Vaccine effectiveness was defined as 
1 minus the odds ratio. Effectiveness estimates were 
adjusted for age and all potential confounding variables: 
gender, maternal age, mother’s education, number of 
children younger than 5 years in the household, number 
of children sleeping in the same room, illness in previous 
3 months, previous hospital admission, distance to clinic 
or hospital, malnutrition, and socioeconomic status based 
on asset score.14 We based vaccination status on doses 
received at least 14 days before presentation of the case. 
Since a high proportion of Gambian children are fully 
vaccinated by the age of 12 months, we stratified vaccine 
effectiveness by age 3–11 months and 12 months or older.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication. 
Clinical 
pneumonia* 
(n=17 136)
Radiological 
pneumonia† 
(n=1920)
Pneumococcal 
pneumonia‡ 
(n=265)
Hypoxic clinical 
pneumonia§ 
(n=672) 
Age
2–11 months 7606 (44%) 774 (40%) 90 (34%) 362 (54%)
12–23 months 5223 (30%) 588 (31%) 74 (28%) 189 (28%)
2–4 years 4307 (25%) 558 (29%) 101 (38%) 121 (18%)
Male 9676 (56%) 1045 (54%) 149 (56%) 345 (51%)
Weight-for-height Z score less than –3, 
age 2–59 months¶
2121 (12%) 279 (15%) 45 (17%) 116 (17%)
Treated as inpatient 10 309 (60%) 1599 (83%) 243 (92%) 643 (96%)
Length of hospital stay, days 3·5 (2·4) 3·8 (2·3) 4·8 (3·4) 3·9 (2·9)
Mortality 379 (2%) 47 (2%) 27 (10%) 81 (12%)
Data are n (%) or mean (SD). Patients were identified in Basse Health and Demographic Surveillance System between 
May 12, 2008, and Dec 31, 2015. *Defined as acute cough or shortness of breath with raised respiratory rate for age, 
inability to feed or sit, reduced conscious state, convulsions, lower chest wall indrawing, peripheral arterial oxygen 
saturation less than 93%, dull chest percussion note, or bronchial breathing on auscultation. †Defined in accordance 
with the WHO standard for childhood radiological pneumonia with consolidation.10 ‡Defined as clinical pneumonia 
with isolation of Streptococcus pneumoniae from a normally sterile site. §Defined as clinical pneumonia with peripheral 
arterial O2 saturation less than 90% at presentation. ¶Defined with the 2006 WHO anthropometry standards. 
Table 1: Characteristics of children with pneumonia by category of pneumonia
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Results
3837 of 4036 children born in the last 6 months of 2014 
had received two or more doses of PCV13 before age 
12 months, giving a coverage of 95%. Coverage of at least 
two doses of PCV13 in the 2–23 month age group 
plateaued at about 70% in early 2014 (appendix p 9).
21 852 patients were screened in the BHDSS for 
referral to a clinician (figure 1). Surveillance was 
maintained at a consistently high level (appendix 
pp 10–12). Overall, 17 136 children aged 2–59 months met 
the criteria for clinical pneumonia (figure 1) and 
1920 children had radiological pneumonia (table 1). 
Mortality from clinical and radiological pneumonia was 
similar. However, mortality was significantly higher in 
pneumococcal versus other pneumonia cases (p<0·0001) 
and hypoxic pneumonia versus other pneumonia cases 
(p<0·0001).
The incidence of radiological pneumonia in the 
2–11 month age group fell from 21·0 cases per 
1000 person-years before PCV introduction, to 16·3 cases 
per 1000 person-years in 2011, declined further to 
10·1 cases per 1000 person-years in 2012 after the 
introduction of PCV13, increased to 20·2 cases per 
1000 person-years in 2013, and then fell to 16·2 in 
2014–15 (figure 2). The pattern was similar in the older 
age groups although without an increase in 2013.
In the baseline period from May 12, 2008, to 
May 11, 2010, 477 cases (565 adjusted) of radiological 
pneumonia were recorded (table 2). In the 2014–15 
period, there were 687 cases (544 adjusted). Crude and 
adjusted numbers of cases differed substantially, 
showing that the crude analyses were affected by the 
increased rate of referrals to clinicians over time. 
Between the baseline period and 2014–15, the adjusted 
incidence of radiological pneumonia declined from 
21·0 to 16·2 cases per 1000 person-years (23% decline, 
95% CI 7–36) in children aged 2–11 months, from 15·3 to 
10·9 cases per 1000 person-years (29% decline, 12–42) in 
children aged 12–23 months, and from 5·2 to 4·1 cases 
per 1000 person-years (22% decline, 1–39) in children 
aged 2–4 years.
Across all age groups, incidence of pneumococcal 
pneumonia declined by 63% (47–74), from 180 to 
65 cases per 1000 person-years (declined from 2·9 to 
1·2 cases per 1000 person-years [58% decline, 22–77] in 
children aged 2–11 months and from 2·6 to 0·7 cases 
per 1000 person-years [75% decline, 47–88] in children 
aged 12–23 months). Pneumonia caused by PCV13 
serotypes declined by 86% (75–92), from 145 to 17 cases 
per 1000 person-years. The incidence of pneumonia due 
to non-PCV13 serotypes did not increase significantly 
(IRR 1·50, 95% CI 0·86–2·61). 
Figure 2: Adjusted annual pneumonia incidence
Incidence of radiological pneumonia with consolidation (A), clinical pneumonia (B), pneumococcal pneumonia (C), and hypoxic pneumonia (D) in the Basse Health and Demographic Surveillance 
System from 2008 to 2015, by age group. Bars show 95% CI. PCV=pneumococcal conjugate vaccine. 
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The incidence of clinical pneumonia was not 
significantly different between the baseline and 2014–15 
periods (table 2). Cases of clinical pneumonia admitted to 
hospital declined by 8% (3–13), from 4250 to 3969 cases 
per 1000 person-years, across all age groups, with the 
greatest absolute reduction occurring in the 2–11 month 
age group, from 107·4 cases per 1000 person-years at 
baseline to 98·1 cases per 1000 person-years in 2014–15.
There was a 61% (95% CI 52–68) fall in the incidence 
of hypoxic pneumonia in all age groups; in the 
2–11 month age group, incidence fell from 13·1 cases 
per 1000 person-years at baseline to 5·7 cases per 
1000 person-years in 2014–15 (57% decline, 42–67), and 
in the 12–23 month age group, incidence fell by from 
6·8 to 1·9 cases per 1000 person-years (72% decline, 
58–82; table 2). Bronchiolitis incidence fell by 39% 
May 12, 2008, to May 11, 2010 2014–15 Incidence rate ratio for 2014–15 vs May 
12, 2008, to May 11 (95% CI)
Cases Incidence per 
1000 person-years
Cases Incidence per 
1000 person-years
Crude Adjusted
Crude Adjusted Crude Adjusted Crude Adjusted Crude Adjusted
Age 2–11 months
Radiological pneumonia with consolidation 180 213 17·8 21·0 288 213 21·9 16·2 1·23 (1·02–1·48) 0·77 (0·64–0·93)
Admitted to hospital 154 182 15·2 18·0 214 181 16·3 13·8 1·07 (0·87–1·32) 0·77 (0·62–0·94)
Pneumococcal 13 15 1·3 1·5 7 6 0·5 0·4 0·41 (0·17–1·04) 0·31 (0·12–0·79)
PCV13 vaccine-type 7 8 0·7 0·8 1 1 0·08 0·08 0·11 (0·01–0·89) 0·10 (0·01–0·77)
Non-vaccine-type 6 7 0·6 0·7 6 5 0·5 0·4 0·77 (0·25–2·39) 0·55 (0·17–1·73)
Clinical pneumonia 1421 1693 140·2 167·1 2561 2156 194·6 163·8 1·39 (1·30–1·48) 0·98 (0·92–1·04)
Admitted to hospital 912 1088 90·0 107·4 1534 1291 116·6 98·1 1·30 (1·19–1·41) 0·91 (0·84–0·99)
Hypoxic 111 133 11·0 13·1 89 75 6·8 5·7 0·62 (0·47–0·82) 0·43 (0·33–0·58)
Pneumococcal 25 29 2·5 2·9 19 16 1·4 1·2 0·59 (0·32–1·06) 0·42 (0·23–0·78)
PCV13 vaccine-type 15 17 1·5 1·7 3 3 0·2 0·2 0·15 (0·04–0·53) 0·14 (0·04–0·46)
Non-vaccine-type 10 12 1·0 1·2 16 13 1·2 1·0 1·23 (0·56–2·71) 0·83 (0·38–1·83)
Age 12–23 months
Radiological pneumonia with consolidation 149 184 12·4 15·3 205 167 13·4 10·9 1·08 (0·88–1·34) 0·71 (0·58–0·88)
Admitted to hospital 123 154 10·2 12·8 165 135 10·8 8·8 1·05 (0·83–1·33) 0·69 (0·55–0·87)
Pneumococcal 23 29 1·9 2·4 6 5 0·4 0·3 0·21 (0·08–0·50) 0·14 (0·05–0·35)
PCV13 vaccine-type 21 26 1·7 2·2 2 2 0·1 0·1 0·07 (0·02–0·32) 0·06 (0·01–0·25)
Non-vaccine-type 2 2 0·2 0·2 4 4 0·3 0·3 1·57 (0·29–8·58) 1·57 (0·29–8·58)
Clinical pneumonia 901 1123 74·9 93·3 1857 1519 121·3 99·2 1·62 (1·50–1·75) 1·06 (0·98–1·15)
Admitted to hospital 539 674 44·8 56·0 995 815 65·0 53·3 1·45 (1·30–1·61) 0·95 (0·86–1·05)
Hypoxic 65 82 5·4 6·8 35 29 2·3 1·9 0·42 (0·28–0·64) 0·28 (0·18–0·42)
Pneumococcal 25 31 2·1 2·6 12 10 0·8 0·7 0·38 (0·19–0·75) 0·25 (0·12–0·53)
PCV13 vaccine-type 23 28 ·· 2·3 4 4 0·3 0·3 0·14 (0·05–0·40) 0·11 (0·04–0·32)
Non-vaccine-type 2 2 ·· 0·2 8 7 0·5 0·5 3·14 (0·67–14·8) 2·75 (0·57–13·2)
Age 2–4 years
Radiological pneumonia with consolidation 148 168 4·6 5·2 194 164 4·8 4·1 1·04 (0·82–1·32) 0·78 (0·61–0·99)
Admitted to hospital 119 135 3·7 4·2 147 129 3·6 3·2 0·98 (0·75–1·28) 0·76 (0·58–0·99)
Pneumococcal 24 28 0·7 0·9 14 12 0·3 0·3 0·46 (0·22–0·96) 0·34 (0·16–0·72)
PCV13 vaccine-type 21 23 0·7 0·7 5 5 0·1 0·1 0·19 (0·06–0·57) 0·17 (0·06–0·50)
Non-vaccine type 3 3 0·1 0·1 9 8 0·2 0·2 1·86 (0·42–8·27) 2·12 (0·49–9·19)
Clinical pneumonia 800 910 24·8 28·2 1391 1225 34·4 30·3 1·38 (1·26–1·52) 1·07 (0·98–1·18)
Admitted to hospital 499 569 15·5 17·7 692 609 17·1 15·0 1·10 (0·97–1·25) 0·85 (0·75–0·97)
Hypoxic 38 43 1·2 1·3 27 24 0·7 0·6 0·57 (0·32–0·98) 0·44 (0·26–0·77)
Pneumococcal 33 37 1·0 1·1 22 20 0·5 0·5 0·53 (0·29–0·96) 0·43 (0·24–0·78)
PCV13 vaccine-type 29 33 0·9 1·0 7 6 0·2 0·1 0·19 (0·08–0·48) 0·14 (0·06–0·38)
Non-vaccine-type 4 5 0·1 0·2 15 13 0·4 0·3 2·99 (0·88–10·09) 2·07 (0·66–6·47)
Data are for the baseline period from May 12, 2008, to May 11, 2010, and the 2014–15 period after the introduction of PCV13. Case counts are adjusted for temporal trends in referral of patients meeting screen 
criteria to surveillance clinicians, and rounded to the nearest integer. 95% CIs were calculated with an inflated variance because of overdispersion in the 2–4 years age group. PCV=pneumococcal conjugate vaccine.
Table 2: Crude and adjusted numbers of cases, incidence of pneumonia endpoints, and incidence rate ratios by age group
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(31–47) in the 2–11 month age group, from 51·7 to 
31·4 cases per 1000 person-years, and by 29% (15-41) in 
the 12–23 month age group, from 21·4 to 15·2 cases per 
1000 person-years (appendix pp 13, 20).
The incidence of the control condition, non-
pneumococcal bacterial pneumonia, was not significantly 
different between the baseline and 2014–15 periods 
(appendix pp 14, 23). The prevalence of malaria-positive 
rapid tests was also not significantly different between the 
baseline and 2014–15 periods (appendix p 15). The 
prevalence of malnutrition (weight-for-height Z score <–3) 
was stable throughout the study at about 10% (appendix 
p 16). Estimates of vaccine impact were unchanged in 
stratified analyses excluding outpatients (table 2), cases 
detected only by lung aspiration (appendix p 21), and cases 
of serotype 1 or 5 pneumonia (appendix p 22).
In the case-control study, we identified 794 eligible 
cases of radiological pneumonia with consolidation, of 
whom 733 were included in the analysis, and 2930 eligible 
controls, of whom 2105 were included in the analysis 
(figure 3). Cases were more likely than controls to have 
had low birthweight, a recent illness, previous hospital 
admission, malnutrition, a greater number of children 
younger than 5 years in the household, and to live closer 
to a hospital (appendix p 24). Vaccine effectiveness was 
similar in the crude (odds ratio 0·71, 95% CI 0·43–1·18) 
and adjusted (adjusted odds ratio 0·72, 0·42–1·23) 
analyses (table 3). The adjusted odds ratio to assess 
vaccine effectiveness in the 3–11 month age group was 
0·59 (0·33–1·06) in the crude analysis and 0·57 
(0·30–1·08) in the adjusted analysis. An increasing 
number of doses of PCV13 was associated with increased 
effectiveness in children aged 3–11 months (p=0·026). 
The analysis in children aged 12 months or older had 
insufficient power (ptrend=0·884) because there were only 
four unvaccinated cases and ten unvaccinated controls.
Discussion
The results from our population-based surveillance in 
The Gambia showed an estimated 24% reduction in the 
incidence of radiological pneumonia with consolidation 
in children aged 2–59 months following the introduction 
of PCV. We found substantial reductions in the incidence 
of culture-proven pneumococcal pneumonia caused by 
PCV13 serotypes (86% reduction). Despite a small, non-
significant increase in pneumonia due to non-PCV13 
serotypes, there was a 63% reduction in all pneumococcal 
pneumonia. Although we detected no effect of PCV on 
all clinical pneumonia, which included outpatients, there 
was an 8% reduction in hospital admissions for clinical 
pneumonia, and the incidence of hypoxic pneumonia fell 
by 61%.
Our findings for radiological pneumonia are similar to 
those reported in Israel, where the introduction of PCV 
was associated with a 47% reduction in childhood hospital 
admissions for WHO-defined radiological pneumonia.8 
Our estimated individual-level effectiveness of PCV13 
against radiological pneumonia (table 3) is similar to that 
in the randomised trial of PCV9 in The Gambia.9 
Sampling for invasive pneumococcal disease and routine 
measurement of O2 saturation enabled us to show a large 
effect of PCV against proven pneumococcal pneumonia 
and hypoxic pneumonia. The substantial impact of PCV 
on these two disorders underscores the vaccines capability 
to prevent the most severe forms of pneumonia.
Population-based studies in high-income countries have 
recorded PCV impact and detected 13–72% reductions in 
hospital admissions coded as pneumonia.6,15−22 We found 
only an 8% reduction in hospital admissions for clinical 
pneumonia across all ages. However, in absolute terms 
there was a reduction of 9·3 cases per 1000 person-years in 
the 2–11 month age group which contrasted with the 
reduction of 4·8 cases of radiological pneumonia per 
1000 person-years in the same age group. Our estimate of 
vaccine impact against all clinical pneumonia might have 
been affected by our case definition and setting. Our 
definition included non-specific clinical signs, such as 
convulsions and raised respiratory rate, and when applied 
in a tropical malaria-endemic setting, this could lead to 
misclassification of other illnesses as pneumonia,23,24 biasing 
effect estimates towards the null. A lack of impact of PCV 
against clinical pneumonia has been noted in other 
settings25,26 and is consistent with the 7% efficacy reported in 
the Gambian PCV9 trial.9
The reduction in bronchiolitis that we detected is 
consistent with the reported 16% reduction in 
 441 did not meet age criteria
 300 not resident in study area
 239 received ≥1 dose of PCV7
 83 previously enrolled as cases
 2 congenital malformation
 3 mother or child with 
  HIV infection
 5 declined consent
 34 exited study area
 22 untraced
13 714 radiographs read
1862 cases radiological pneumonia
794 eligible cases identified
733 cases included in analysis
 3 aged <90 days
 4 resident after age 2 months
 2 admitted in past 14 days
 25 died before case enrolment
 408 received ≥1 dose of PCV7
 6 congenital malformation
 2 mother or child with
  HIV infection
 21 declined consent
 233 exited study area
 46 could not be traced
 243 travelled and could not be
  contacted after three visits
 44 had no matched case
3945 home visits made
3142 potential controls identified
2930 eligible controls identified
2105 controls included in analysis
Figure 3: Case-control study profile
The case-control study investigated the effectiveness of PCV13 against radiological pneumonia with consolidation. 
PCV=pneumococcal conjugate vaccine.
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bronchiolitis admissions in infants in the USA following 
the introduction of PCV7.27 The US investigators also 
showed that, following PCV7 introduction, hospital 
admissions for respiratory syncytial virus infection 
declined by 18% in infants and 9% in children aged 
12–23 months. Evidence of synergistic relationships 
between pneumococcus and respiratory viruses was 
provided by a trial in South Africa, in which PCV9 
prevented 31% of hospital admissions for virus-associated 
lower respiratory disease, probably those caused by co-
infections with virus and pneumococcus.28
All screening, investigations, and laboratory practices 
were standardised and consistently applied throughout 
this study. The reading of radiographs was done in 
accordance with the WHO recommendations11 and all 
readers were regularly recalibrated to the WHO standard. 
Measurement of O2 saturation and clinical and 
radiographic findings enabled us to show significant 
impact of PCV against the novel endpoints of hypoxic 
pneumonia and bronchiolitis. The limitations of this 
study include the relatively short baseline period and the 
need for adjustment of annual case counts to account for 
increased referrals of patients over time. Our adjustment 
of case counts resulted in less precise estimates of 
vaccine impact and an interpretation that assumes 
referrals over time were constant. The adjustment 
accounts for a systematic bias leading to increasing case 
detection during the course of the observation period. 
We, and others, have used this approach in the past.12,29 
The estimates of direct vaccine effectiveness in the 
case-control study support the longitudinal results of a 
significant impact of PCV, while suggesting that the 
longitudinal study might have underestimated the 
impact of the vaccine slightly. The case-control estimate 
might have been affected by biases in either direction; a 
falling proportion of radiological pneumonia caused by 
vaccine serotypes over time would tend to underestimate 
vaccine effectiveness, whereas overestimation is 
possible because of unvaccinated children being at an 
inherently higher risk than vaccinated children in ways 
unrelated to vaccination. In the longitudinal study, the 
baseline period was partly affected by the first few 
months of vaccine implementation, although the effect 
was limited by the absence of a catch-up campaign. 
Coverage of PCV13 in the 2–4 year age group peaked 
later in the PCV13 period, so impact could not be fully 
estimated in this age group. Our study has several 
features that help to alleviate some concerns of bias and 
confounding resulting from changes in factors that 
affect the detection or risk of pneumonia: the incidence 
of the control condition, pneumonia due to non-
pneumococcal bacteria, was stable over time, estimates 
of the vaccine impact were unchanged in stratified 
analyses, and there was no difference in the prevalence 
of malaria or malnutrition between the baseline and 
2014–15 periods.
Extended surveillance will be needed to establish the 
maximum impact of PCV13 in the 2–4 year age group, as 
vaccine coverage increases in that age group, and to 
identify the serotypes causing disease in the PCV13 era to 
guide the development of the next generation of vaccines. 
The vaccine impact that we saw resulted from a standard 
EPI schedule without catch-up—ie, the programmatic 
circumstances found in most low-income countries. 
Therefore, other low-income countries that introduce 
PCV with reasonable coverage can expect to have 
significant reductions in hospital admissions for 
pneumonia and substantial reductions in cases of severe 
pneumonia.
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and GAM oversaw it throughout the study. GAM, AA, and DSa trained 
and supervised clinicians and staff on study procedures. SMS, IH, UU, 
DA, MN, CDO, OA, JP, YO, BA, EA, BSM, AEF, RM, BE, RCI, BK, PG, 
EO, OO, EU, and EG clinically evaluated and investigated the patients 
and maintained quality assurance during clinical procedures. SMS, IH, 
RM, and AA read the radiographs in the longitudinal study. SMS, IH, 
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Cases (%) Controls (%) Crude odds ratio 
(95% CI)
Adjusted odds 
ratio (95% CI)
p value 
for trend
Age 3–11 months ·· ·· ·· ·· 0·026
Total 336 969 ·· ·· ··
No doses 38 (11%) 103 (11%) Reference Reference ··
One dose 83 (25%) 198 (20%) 1·09 (0·67–1·79) 1·08 (0·63–1·83) ··
Two doses 87 (26%) 247 (25%) 0·81 (0·47–1·39) 0·83 (0·46–1·50) ··
Three doses 128 (38%) 421 (43%) 0·59 (0·33–1·06) 0·57 (0·30–1·08) ··
Two or three 
doses
215 (64%) 668 (69%) 0·73 (0·43–1·24) 0·74 (0·42–1·32) ··
Age ≥12 months ·· ·· ·· ·· 0·884
Total 397 1136 ·· ·· ··
No doses 4 (1%) 10 (1%) Reference Reference ··
One dose 9 (2%) 16 (1%) 1·64 (0·35–7·74) 1·29 (0·26–6·36) ··
Two doses 18 (5%) 49 (4%) 1·28 (0·32–5·10) 0·74 (0·17–3·16) ··
Three doses 366 (92%) 1061 (93%) 1·21 (0·33–4·48) 0·93 (0·24–3·64) ··
Two or three 
doses
384 (97%) 1110 (98%) 1·22 (0·33–4·52) 0·73 (0·23–3·49) ··
Overall ·· ·· ·· ·· 0·067
Total 733 2105 ·· ·· ··
No doses 42 (6%) 113 (5%) Reference Reference ··
One dose 92 (13%) 214 (10%) 1·15 (0·72–1·83) 1·12 (0·68–1·82) ··
Two doses 105 (14%) 296 (14%) 0·87 (0·53–1·44) 0·84 (0·50–1·43) ··
Three doses 494 (67%) 1482 (70%) 0·71 (0·43–1·18) 0·72 (0·42–1·23) ··
Two or three 
doses
599 (82%) 1778 (84%) 0·79 (0·49–1·28) 0·78 (0·47–1·30) ··
Radiological pneumonia with consolidation was defined in accordance with WHO criteria. Adjusted odds ratios  were 
calculated from a conditional logistic regression model adjusted for age, gender, maternal age, mother’s education, 
number of children younger than 5 years in the household, number of children sleeping in the same room, illness in 
previous 3 months, previous hospital admission, distance to clinic or hospital, malnutrition, and socioeconomic status 
based on asset score. PCV13=13-valent pneumococcal conjugate vaccine.
Table 3: Case-control analysis of PCV13 against radiological pneumonia with consolidation
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